Scinai Immunotherapeutics Ltd. Sponsored ADR (NASDAQ:SCNI) Short Interest Update

Scinai Immunotherapeutics Ltd. Sponsored ADR (NASDAQ:SCNI) was the target of a significant increase in short interest during the month of July. As of July 15th, there was short interest totaling 455,184 shares, an increase of 1,589.7% from the June 30th total of 26,939 shares. Based on an average daily volume of 925,479 shares, the short-interest ratio is presently 0.5 days. Approximately 29.4% of the company’s shares are sold short.

Analyst Ratings Changes

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Scinai Immunotherapeutics in a research note on Friday, July 17th. One research analyst has rated the stock with a Sell rating, According to MarketBeat, the stock currently has an average rating of “Sell”.

Scinai Immunotherapeutics Trading Down 6.9%

Shares of NASDAQ:SCNI traded down $0.02 during mid-day trading on Friday, hitting $0.23. The stock had a trading volume of 35,206 shares, compared to its average volume of 541,542. The company has a debt-to-equity ratio of 0.05, a quick ratio of 1.35 and a current ratio of 1.35. The company has a market cap of $910,800.00, a PE ratio of -0.22 and a beta of 2.11. Scinai Immunotherapeutics has a 12-month low of $0.21 and a 12-month high of $3.48. The company’s 50 day moving average is $0.34 and its 200-day moving average is $0.60.

Institutional Trading of Scinai Immunotherapeutics

A hedge fund recently raised its stake in Scinai Immunotherapeutics stock. Citadel Advisors LLC increased its holdings in shares of Scinai Immunotherapeutics Ltd. Sponsored ADR (NASDAQ:SCNI) by 146.8% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 28,630 shares of the company’s stock after buying an additional 17,031 shares during the quarter. Citadel Advisors LLC owned 0.90% of Scinai Immunotherapeutics worth $36,000 as of its most recent filing with the Securities and Exchange Commission. Hedge funds and other institutional investors own 58.41% of the company’s stock.

About Scinai Immunotherapeutics

Scinai Immunotherapeutics Inc is a clinical-stage biotechnology company dedicated to developing novel small-molecule therapies that enhance the immune system’s capacity to recognize and destroy cancer cells. The company’s research emphasizes checkpoint modulation and the discovery of compounds designed to work in concert with established immuno-oncology treatments across a range of solid tumors.

Scinai’s pipeline comprises preclinical and early-stage candidates, and the company relies on collaborations with academic institutions and contract research organizations to advance its discovery and development efforts.